Logotype for Cherry AG

Cherry (C3RY) Q1 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Cherry AG

Q1 2026 earnings summary

12 Aug, 2026

Executive summary

  • Q1 2026 saw operational improvements and organizational simplification through Project Blossom, targeting sustainable profitability and EBITDA/EBIT breakeven by 2027.

  • Revenue declined 17.8% year-over-year to EUR 20.8 million, mainly due to weak demand in Gaming & Office Peripherals and strategic realignment.

  • Digital Health & Solutions (DH&S) segment delivered strong growth, with revenue more than tripling year-over-year, driven by regulatory mandates and delayed telematic infrastructure rollout in Germany.

  • Peripherals business is being repositioned for profitable growth, focusing on core input devices, asset-light operations, and a leaner, scalable model.

  • Major milestones include improved OPEX control, positive free cash flow, and management board changes to streamline operations.

Financial highlights

  • Group revenue for Q1 2026 was EUR 20.8 million, down 17.8% year-over-year due to one-off effects, weak demand, and FX headwinds.

  • Adjusted EBITDA improved to minus EUR 600,000 (margin -2.9%) from minus EUR 2 million (margin -8.0%) in Q1 2025, with margin up over 5 percentage points year-over-year.

  • Free cash flow was positive at EUR 1.1 million, about EUR 10 million better than last year, mainly from working capital management.

  • Gross margin increased to 46.7% from 43.7% year-over-year, reflecting better pricing and product mix.

  • Net loss narrowed to EUR 4.0 million from EUR 5.8 million year-over-year, driven by reduced operating costs and lower depreciation.

Outlook and guidance

  • No reliable full-year outlook provided due to ongoing M&A process and incomplete 2025 financials; more details expected next quarter.

  • Project Blossom targets EBITDA/EBIT breakeven in 2027, with targeted OPEX savings and revenue growth across office, gaming, and security segments.

  • DH&S segment is well-positioned in the German e-health market, with recurring revenue and strong regulatory-driven demand.

  • Peripherals business transformation aims for a leaner, scalable model with higher margins and cash generation.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more